Takeda and Sanofi Strike Diabetes Drug Co-Promotion in China

Takeda and Sanofi agreed to co-promote Takeda’s Alogliptin, a DPP-4 treatment for type 2 diabetes, in China. Under the terms of the agreement, Sanofi will have the exclusive right to promote the drug in certain defined territories in China. Alogliptin is currently being reviewed for marketing by the SFDA; Takeda expects an approval sometime this year. Terms of the agreement were not disclosed. More details.... Stock Symbols: (TO: 4502) (NYSE: SNY) Share this with colleagues: // //